Short answer
Edgewise Therapeutics, Inc. (EWTX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$49M
- −20.1% YoY
- EPS (diluted)
- −$0.46
- −7.0% YoY
Source: XBRL data from the Edgewise Therapeutics, Inc. (EWTX) Q1 2026 10-Q on SEC EDGAR. USD.
Edgewise Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; no product revenue since inception
- Net loss $49.0M vs $40.8M YoY; operating expenses $54.1M vs $46.0M
- Best program EDG-15400 expenses $3.1M, newly separated after Phase 1 advancement; sevasemten expenses declined $0.9M
- Cash, equivalents and marketable securities $499.6M; operating cash use $42.5M vs $37.9M YoY
- Near-term funding through at least next 12 months; higher spending expected for clinical development, regulatory approvals and personnel growth
Risk Factors
- No new or changed risk factors identified; section presents established risks without comparison to the prior 10-K
- Liquidity risk: $499.6M in cash, equivalents and marketable securities expected to fund operations for at least 12 months
- Financing risk: Additional capital required because current resources cannot fund product candidates through regulatory approval
- Regulatory risk: FDA-required manufacturing changes may trigger additional clinical trials or bridging studies
- Operational risk: Third-party manufacturers may fail to supply adequate quantities or quality for clinical trials and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Edgewise Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.